CTI BIOPHARMA CORP - FORM 10-K - EX-21.1 - EXHIBIT 21.1 - February 16, 2016

Attached files

file filename
10-K - 10-K - CTI BIOPHARMA CORPcti10k12312015document.htm
EX-31.1 - EXHIBIT 31.1 - CTI BIOPHARMA CORPexhibit311sect302certceo.htm
EX-31.2 - EXHIBIT 31.2 - CTI BIOPHARMA CORPexhibit312sect302certcfo.htm
EX-32 - EXHIBIT 32 - CTI BIOPHARMA CORPexhibit32sect906certceocfo.htm
EX-10.36 - EXHIBIT 10.36 - CTI BIOPHARMA CORPexhibit1036ltipamendmentjb.htm
EX-12.1 - EXHIBIT 12.1 - CTI BIOPHARMA CORPexhibit121ratioofearningst.htm
EX-10.11 - EXHIBIT 10.11 - CTI BIOPHARMA CORPexhibit1011smtseveranceagr.htm
EX-10.37 - EXHIBIT 10.37 - CTI BIOPHARMA CORPexhibit1037ltipamendmentmp.htm
EX-23.1 - EXHIBIT 23.1 - CTI BIOPHARMA CORPexhibit231accountingfirmco.htm
EX-10.5 - EXHIBIT 10.5 - CTI BIOPHARMA CORPexhibit105amendment3todrbi.htm
EX-10.35 - EXHIBIT 10.35 - CTI BIOPHARMA CORPexhibit1035seeleyltipaward.htm
EX-10.12 - EXHIBIT 10.12 - CTI BIOPHARMA CORPexhibit1012directorcompens.htm



Exhibit 21.1
Subsidiaries of CTI BioPharma Corp.
Aequus Biopharma, Inc., a Washington corporation; Systems Medicine, LLC, a Delaware limited liability company; and CTI Life Sciences Ltd., a U.K. limited company.
The above paragraph includes all material subsidiaries of CTI BioPharma Corp.



Stock widget

Investing forum

CTI BIOPHARMA CORP Reports